Qube Research & Technologies (QRT)
PLX icon

Qube Research & Technologies (QRT)’s Protalix BioTherapeutics PLX Stock Holding History

Qube Research & Technologies (QRT)’s Portfolio PLX Stock Details PLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-118,808
Closed -$304K – 3882
2025
Q1 		$304K Buy
118,808
+93,941
+378% +$224K ﹤0.01% 2725
2024
Q4 		$46.8K Sell
24,867
-11,571
-32% -$16.4K ﹤0.01% 3104
2024
Q3 		$37.2K Sell
36,438
-84,592
-70% -$89K ﹤0.01% 2902
2024
Q2 		$142K Buy
+121,030
New +$143K ﹤0.01% 2522

Other funds holding PLX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $43.4B AUM 51.29% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SWP
Stratos Wealth Partners Beachwood, Ohio $8.8B AUM 21.82% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Qube Research & Technologies (QRT)'s PLX Position: Q2 2025 in Review

Qube Research & Technologies (QRT) sold out of Protalix BioTherapeutics (PLX) in Q2 2025, closing a stake of 118,808 shares — an estimated $304K sold.

Qube Research & Technologies (QRT) first reported a position in PLX in Q2 2024 and held it in 4 quarters. The position peaked at $304K in Q1 2025. 63 funds tracked by Wall St. Rank hold PLX as of Q2 2025.

  • Qube Research & Technologies (QRT) reported no remaining Protalix BioTherapeutics position as of Q2 2025 after selling out during the quarter.
  • Qube Research & Technologies (QRT) sold 118,808 Protalix BioTherapeutics shares in Q2 2025, an estimated $304K.
  • Qube Research & Technologies (QRT) first reported a position in Protalix BioTherapeutics in Q2 2024 and held it in 4 quarters.
  • Qube Research & Technologies (QRT)'s Protalix BioTherapeutics position peaked at $304K in Q1 2025.
  • 63 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q2 2025.

Based on Qube Research & Technologies (QRT)'s 13F filing for Q2 2025, filed 14 Aug 2025.